“Overall, we expect Kite revenue to decline approximately 10% in 2026 compared to 2025.”

In context

“ear reflecting ongoing in and out of class competition. For the fourth quarter, cell therapy sales were $458 million, up 6% sequentially due to higher than expected patient treatments in advance of holidays, in addition to one-time pricing adjustments. Year over year, fourth quarter cell therapy sales were down 6% consistent with the trends we have discussed throughout 2025. For 2026, we continue to expect these competitive headwinds including in several countries outside the US, where we expect new entrants this year. Additionally, cell therapy volumes are being impacted by a growing number of clinical trials, which is exciting for our industry and for the patients who could benefit from innovative new therapies from Kite and others. That said, this represents another near-term headwind. Overall, we expect Kite revenue to decline approximately 10% in 2026 compared to 2025. Looking to the second half of the year, the team is preparing for the potential launch of Anidocel in fourth-line and later relapsed or refractory multiple myeloma. We believe Anidocel's potential best-in-disease profile combined with Kite's exceptional manufacturing capabilities, and industry-leading turnaround times, puts us in a favorable position ahead of a potential commercial launch. Wrapping up our fourth quarter and 2025 on slide 16, I'd like to highlight the exceptional strength of our existing commercial portfolio as well as our robust launch pipeline with the potential for four launches later this year. We are committed to remaining focused on our ongoing launches of Libdelzi and YES2GO. In addition to ensuring that we are prepared to have an immediate impact with the potential”